Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;65(2):251-276.
doi: 10.1007/s12016-023-08969-x. Epub 2023 Aug 21.

Treatable Traits in Systemic Sclerosis

Affiliations
Review

Treatable Traits in Systemic Sclerosis

Francesco Amati et al. Clin Rev Allergy Immunol. 2023 Oct.

Abstract

Systemic sclerosis (SSc) is a chronic systemic disease within the spectrum of connective tissue diseases, specifically characterized by vascular abnormalities and inflammatory and fibrotic involvement of the skin and internal organs resulting in high morbidity and mortality. The clinical phenotype of SSc is heterogeneous, and serum autoantibodies together with the extent of skin involvement have a predictive value in the risk stratification. Current recommendations include an organ-based management according to the predominant involvement with only limited individual factors included in the treatment algorithm. Similar to what has been proposed for other chronic diseases, we hypothesize that a "treatable trait" approach based on relevant phenotypes and endotypes could address the unmet needs in SSc stratification and treatment to maximize the outcomes. We provide herein a comprehensive review and a critical discussion of the literature regarding potential treatable traits in SSc, focusing on established and candidate biomarkers, with the purpose of setting the bases for a precision medicine-based approach. The discussion, structured based on the organ involvement, allows to conjugate the pathogenetic mechanisms of tissue injury with the proposed predictors, particularly autoantibodies and other serum biomarkers. Ultimately, we are convinced that precision medicine is the ideal guide to manage a complex condition such as SSc for which available treatments are largely unsatisfactory.

Keywords: Autoimmune disorder; Systemic sclerosis; Treatable trait.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390:1685–1699 - PubMed - DOI
    1. Bairkdar M, Rossides M, Westerlind H, Hesselstrand R, Arkema EV, Holmqvist M (2021) Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology 60:3121–3133 - PubMed - PMC - DOI
    1. Cavazzana I, Vojinovic T, Airo’ P, Fredi M, Ceribelli A, Pedretti E, Lazzaroni MG, Garrafa E, Franceschini F (2022) Systemic sclerosis-specific antibodies: novel and classical biomarkers. Clin Rev Allergy Immunol. https://doi.org/10.1007/s12016-022-08946-w - DOI - PubMed - PMC
    1. Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327–1339 - PubMed - DOI
    1. Poddubnyy D (2021) Precision medicine in rheumatology: are we getting closer? Lancet 397:258–259 - PubMed - DOI

LinkOut - more resources